Biotech Values

[genisi]

specific VEGFR inhibitors in the clinic

Brivanib is a selective receptor tyrosine kinase inhibitor that targets VEGF-R2 and FGF-R1/2.

Pegdinetanib is a highly specific VEGF-R2 inhibitor.

Cediranib inhibits all three vascular endothelial growth factor receptor (VEGF-1,-2,-3) tyrosine kinases and has activity against c-Kit, PDGFR-ß and FIT-4.

Pazopanib selectively inhibits all three VEGFRs, c-Kit and PDGF-R.

Lenvatinib is a specific VEGF-R2/3 inhibitor.

Motesanib selectively targets and inhibits all three VEGFRs, PDGFR, kit, and Ret receptors